Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 5:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Chiron Corporation Clear all
Completed Not applicable Interventional

Effectiveness of Adding Interleukin-2 to Anti-HIV Drugs in Patients Recently Infected With HIV

NCT00006441
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine/Zidovudine, Nelfinavir mesylate, Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
2
States / cities
Birmingham, Alabama • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Oct 4, 2026, 5:49 AM EDT
Terminated Phase 2 Interventional

Tezacitabine and Oxaliplatin for the Treatment of Patients With Metastatic Colorectal Cancer

NCT00051688
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
tezacitabine, oxaliplatin
Drug
Lead sponsor
Chiron Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
8
States / cities
Tucson, Arizona • Los Angeles, California • Palm Springs, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2006 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 3 Interventional Results available

An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy

NCT00004978
View directory record Official record
Conditions
HIV Infections
Interventions
Recombinant interleukin-2 (rIL-2)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
4,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
78
States / cities
Los Angeles, California • Mill Valley, California • Oakland, California + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 3 Interventional

Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer

NCT00003126
View directory record Official record
Conditions
Kidney Cancer
Interventions
Interleukin-2
Drug
Lead sponsor
Loyola University
Other
Eligibility
16 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
15
States / cities
Duarte, California • Los Angeles, California • Oakland, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2017 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 2 Interventional

Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer

NCT00100906
View directory record Official record
Conditions
Kidney Cancer
Interventions
IL-2, ATRA
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 16, 2013 · Synced Oct 4, 2026, 5:49 AM EDT
Not listed Phase 1 Interventional

Safety and Effectiveness of L2-7001 (Interleukin-2) in HIV-Positive Patients Receiving Anti-HIV Therapy

NCT00002449
View directory record Official record
Conditions
HIV Infections
Interventions
Aldesleukin
Drug
Lead sponsor
Chiron Corporation
Industry
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
23
States / cities
Birmingham, Alabama • Beverly Hills, California • Fountain Valley, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 2 Interventional

Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma

NCT00616564
View directory record Official record
Conditions
Malignant Melanoma
Interventions
GM-CSF
Drug
Lead sponsor
Mt. Sinai Medical Center, Miami
Other
Eligibility
16 Years to 90 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Miami Beach, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 2 Interventional

Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.

NCT00045864
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
Recombinant Human Interleukin-2 and Rituximab
Drug
Lead sponsor
Chiron Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
33
States / cities
Tucson, Arizona • Newport Beach, California • Sacramento, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2006 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 1 Interventional

Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies

NCT00061620
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Tezacitabine (FMdC)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 4 Interventional

Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

NCT00006864
View directory record Official record
Conditions
Kidney Cancer
Interventions
aldesleukin
Biological
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
2
States / cities
Torrington, Connecticut • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 2Phase 3 Interventional

Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments

NCT00045877
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
Recombinant Human Interleukin-2 and Rituximab
Drug
Lead sponsor
Chiron Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
65
States / cities
Little Rock, Arkansas • Bakersfield, California • Fresno, California + 57 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2006 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 2 Interventional

Tezacitabine With or Without 5-Fluorouracil (5-FU) for Advanced Esophageal Cancer or Gastric Cancer

NCT00054873
View directory record Official record
Conditions
Esophageal Neoplasms, Stomach Neoplasms, Adenocarcinoma
Interventions
tezacitabine, 5-fluorouracil
Drug
Lead sponsor
Chiron Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
29
States / cities
Birmingham, Alabama • Tucson, Arizona • Glendale, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2006 · Synced Oct 4, 2026, 5:49 AM EDT
Terminated Phase 2 Interventional

Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)

NCT00100737
View directory record Official record
Conditions
Non-Hodgkin Lymphoma
Interventions
interleukin-2, rituximab
Drug
Lead sponsor
Chiron Corporation
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2006 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 2 Interventional Results available

Effect of Intermittent Aldesleukin Treatment With or Without Anti-HIV Drugs in HIV Infected People

NCT00110812
View directory record Official record
Conditions
HIV Infections
Interventions
IL-2
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
11
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Bethesda, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 1 Interventional

A Phase I Study of Subcutaneously Administered Proleukin (Aldesleukin) in HIV-Infected Patients

NCT00002107
View directory record Official record
Conditions
HIV Infections
Interventions
Aldesleukin
Drug
Lead sponsor
Chiron Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 4, 2026, 5:49 AM EDT
Terminated Phase 2 Interventional

Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's Lymphoma

NCT00250861
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Rituximab, Aldesleukin
Drug
Lead sponsor
US Oncology Research
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Timeline
2005 – 2007
U.S. locations
21
States / cities
Denver, Colorado • Chicago, Illinois • Niles, Illinois + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2008 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I, Observer-Blind, Placebo-Controlled Study of the Chiron Vaccine HIV p24/MF59 Administered to Healthy HIV-Seronegative Adults

NCT00002204
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
HIV p24/MF59 Vaccine
Biological
Lead sponsor
Chiron Corporation
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Not applicable Interventional

Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine or Dideoxyinosine in HIV Positive, Asymptomatic and Symptomatic Individuals

NCT00001997
View directory record Official record
Conditions
HIV Infections
Interventions
Interleukin-2, Polyethylene Glycolated, Zidovudine, Didanosine
Drug
Lead sponsor
Chiron Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 2 Interventional

Phase II Study of a B7-1 Gene-Modified Autologous Tumor Cell Vaccine and Systemic IL-2

NCT00031564
View directory record Official record
Conditions
Kidney Cancer
Interventions
Interleukin-2, B7-1
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 27, 2012 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 1 Interventional

A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis

NCT00002321
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Aldesleukin
Drug
Lead sponsor
Chiron Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 4, 2026, 5:49 AM EDT